Aphton Announces Application for Fast Track Designation Filed With FDA For Its Anti-Gastrin Immunogen G17DT for Treatment of Pancreatic Cancer.
Business Wire › August 19, 2002
Linked as:
Extract
Aphton Announces Application for Fast Track Designation Filed With FDA For Its Anti-Gastrin Immunogen G17DT for Treatment of Pancreatic Cancer.
Business Editors & Health/Medical Writers
BIOWIRE 2K MIAMI--(BW HealthWire)--Aug. 19, 2002 Aphton Corporation (NASDAQ NMS: APHT) - Aphton announced today that it has filed an application with the FDA for Fast Track designation for its anti-gastrin imm...See the full content of this document
Sponsored links
